Post the revelation that 12 known command-and-control (C&C) servers for...
Researchers have said that an experimental AstraZeneca drug has the capability to slow the progression of an ovarian cancer in patients who have had positive effects from chemotherapy.
Olaparib, a drug which is presently in the second phase of the testing, is also known as the maintenance therapy and this slows down the progression of ovarian cancer to as much as 4 months. However, this drug only becomes effective if the patient has been given 2 dosages of chemotherapy. This information was obtained during a brief introduction regarding this drug.
It has been said that people who consume this drug twice a day will have progression free survival for around 8 months after which cancer will become progressive.
The researchers claimed that these results were highly significant. This drug will be able to slow down the progression and add some lifetime for the patient.
"A well-tolerated antitumor agent that could be used for months or perhaps years as maintenance therapy after standard chemotherapy could be a big step forward and ultimately extend survival", Dr. Jonathan Ledermann, the study's primary investigator, said in a statement.
The survival data of this drug is not yet available and this study has already been done on 265 patients with the common form of ovarian cancer and also those who have shown improvement from chemotherapy.